Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and autoimmune diseases on people’s lives is why we’re here

Research and development

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

An immunotherapy platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ immunotherapy has the potential to treat many disease areas, including cancer.

Highlights

Nykode Therapeutics – Invitation to Q1 2026 Financial Results ...

Read More
18 May 2026

Nykode Therapeutics Doses First Patient in Abili-T Phase II ...

Read More
07 May 2026

Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma ...

Read More
30 April 2026

Nykode Therapeutics Presents Additional Immunogenicity Data from VB-C-03 Trial ...

Read More
20 April 2026

Nykode Therapeutics – Annual Report 2025

Read More
17 April 2026

Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity ...

Read More
20 March 2026

Nykode Therapeutics Announces Upcoming Presentations at AACR 2026 and ...

Read More
18 March 2026

Nykode Therapeutics to Present at DNB Carnegie Conference on ...

Read More
09 March 2026

Nykode Therapeutics to Present New Data and Participate in ...

Read More
03 March 2026